+CD8(+) T, 0, 83 mRNA?, CCR4, CCR6, CCR6(-)CXCR3(-) cells, CD3, CD3(+), CD3(+) CD4(+) IL-9(+) Th9 cells, CD3(+)CD4(+)IL, CD3(+)CD4(+)IL-9(+)Th9, CD4, CD4(+, CD4(+), CD4(+) CCR4(-), CD4(+) CCR4(-)CCR6(-)CXCR3(, CD4(+) CCR4(-)CCR6(-)CXCR3(-) cells, CD4(+) CCR4(-)CCR6(-)CXCR3(-)cells, CD4(+) T cells, CD8, CD8(+, CD8(+), CD8(+) T, CD8(+) T cell, CD8(+) T cells, CXCR3, ELIS mRNA, IL-17, IL-22, IL-9, IL-9 mRNA, IL-9(+, LDH, PBMCs, PU.1, PU.1 mRNA, Purified CD8(+) T cells, Recombinant human IL-9, STAT3, STAT6, TILSs, TILs, TNF-, TNF-?, Th9, Th9 cells, Tumor-infiltrating Th9 cells, Tumor-infiltrating lymphocytes, anti-IL-9, anti-IL-9 neutralizing, autologous gastric cancer cells, culture systems, gastric, gastric cancer, gastric cancer cells, human, interleukin-9, lactate, lactate dehydrogenase, mRNA, mRNA?, patients, peripheral blood mononuclear cells, purine, purine-rich nucleic acid binding protein 1, recombinant human IL-9, signal transducer and activator of transcription 3, target cell, target cells, tumor, tumor necrosis factor-?, tumor-infiltrating CD8(+) T cells, tumor-infiltrating Th9 cells